# A Clinical Study on TIL for the Treatment of Advanced Solid Tumors

> **NCT05087745** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shanghai Juncell Therapeutics** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Tumor Infiltrating Lymphocytes
- Treatment Side Effects
- Effects of Immunotherapy

## Interventions

- **BIOLOGICAL:** Tumor Infiltrating Lymphocytes

## Key facts

- **NCT ID:** NCT05087745
- **Lead sponsor:** Shanghai Juncell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-10
- **Primary completion:** 2024-12-10
- **Final completion:** 2025-12-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05087745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05087745, "A Clinical Study on TIL for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05087745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*